We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review.
- Authors
Angula, Klaudia T.; Legoabe, Lesetja J.; Beteck, Richard M.; de Sousa, Maria Emília
- Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a curable airborne disease currently treated using a drug regimen consisting of four drugs. Global TB control has been a persistent challenge for many decades due to the emergence of drug-resistant Mtb strains. The duration and complexity of TB treatment are the main issues leading to treatment failures. Other challenges faced by currently deployed TB regimens include drug-drug interactions, miss-matched pharmacokinetics parameters of drugs in a regimen, and lack of activity against slow replicating sub-population. These challenges underpin the continuous search for novel TB drugs and treatment regimens. This review summarizes new TB drugs/drug candidates under development with emphasis on their chemical classes, biological targets, mode of resistance generation, and pharmacokinetic properties. As effective TB treatment requires a combination of drugs, the issue of drug-drug interaction is, therefore, of great concern; herein, we have compiled drug-drug interaction reports, as well as efficacy reports for drug combinations studies involving antitubercular agents in clinical development.
- Subjects
DRUG development; DRUG interactions; MYCOBACTERIUM tuberculosis; DRUG target; MULTIDRUG-resistant tuberculosis; ANTITUBERCULAR agents; TUBERCULOSIS; AIRBORNE infection
- Publication
Pharmaceuticals (14248247), 2021, Vol 14, Issue 5, p461
- ISSN
1424-8247
- Publication type
Article
- DOI
10.3390/ph14050461